Pharmaceutical News

RSS

Preoperative statins linked to reductions in cardiac complications, mortality after noncardiac surgery

Preoperative statins are associated with a 17% reduction in cardiac complications and a 43% reduction in mortality after noncardiac surgery, according to results from the VISION Study presented for the first time today at ESC Congress by Dr Otavio Berwanger, director of the Research Institute HCor, Hospital do Coração (Heart Hospital) in São Paulo, Brazil.

1 Sep 2015

Benznidazole has significant antiparasitic activity, but does not reduce progression of Chagas cardiomyopathy

A 40 to 80 day treatment with the antiparasitic medication benznidazole significantly reduced parasite activity in the blood, but not progression, of serious heart problems over a 5-year period among patients with established Chagas disease (CD) cardiomyopathy, results of the BENEFIT trial show.

1 Sep 2015

AMRI, Saneca Pharmaceuticals collaborate to develop and market opium-derived APIs

AMRI and Saneca Pharmaceuticals, a.s. today announced a strategic collaboration focused on the development, manufacture and marketing of a portfolio of opium-derived active pharmaceutical ingredients, ("APIs").

31 Aug 2015

LCZ696 reduces aortic systolic blood pressure, pulse pressure in hypertensive patients

The combination drug valsartan/sacubitril known as LCZ696 significantly reduced aortic systolic blood pressure and pulse pressure compared to the standard angiotensin receptor blocker (ARB) olmesartan in patients with hypertension, according to results of the PARAMETER study.

31 Aug 2015

Educational program does not influence patients’ adherence to apixaban anticoagulant

Adherence to the oral anticoagulant apixaban among patients with atrial fibrillation (AF) was no better for those who received an educational program compared to those who did not, results of the international, randomised AEGEAN trial show.

31 Aug 2015

TECOS analysis shows sitagliptin safe and effective in patients with type-2 diabetes, cardiovascular disease

Patients with type-2 diabetes and cardiovascular disease can safely take the antihyperglycemic drug sitagliptin without an increased risk of cardiovascular complications - even if they have a history of heart failure - a new analysis of the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) study shows.

31 Aug 2015

ATTEMPT-CVD trial results show that ARBs may have better impact on CVD biomarkers

When it comes to treating high blood pressure, not all anti-hypertensive medications are equal, and results of the ATTEMPT-CVD trial suggest that telmisartan, an angiotensin II receptor blocker (ARB) might have benefits over non-ARB treatment.

31 Aug 2015

MRA therapy does not improve outcome in heart attack patients without heart failure

Heart attack patients without heart failure derive no benefit from the addition of mineralocortoid receptor antagonists (MRA), to standard therapy, results of the ALBATROSS study show.

31 Aug 2015

Cyclosporine drug does not improve outcomes in STEMI patients receiving PCI

The immunosuppressant drug cyclosporine did not improve clinical outcomes compared to placebo in patients receiving percutaneous coronary intervention (PCI) for the more severe form of heart attack known as ST-segment elevation myocardial infarction (STEMI).

31 Aug 2015

Single dose of cocaine can impair ability to recognise negative emotions

A single dose of cocaine can interfere with the ability to recognise negative emotions, according to new research presented at the ECNP conference in Amsterdam.

31 Aug 2015

BPC praises FDA draft guidance on nonproprietary naming of biological products

Biosimilars are not generics and the Biologics Prescribers Collaborative (BPC) applauds the U.S. Food and Drug Administration (FDA) for recognizing that each biosimilar needs a distinguishable name in its draft guidance issued today. The FDA's draft guidance on nonproprietary naming of biological products proposes distinguishable names, calling for biological products to bear a nonproprietary name that includes an FDA-designated suffix.

29 Aug 2015

Fentanyl sold as heroin causing new wave of overdose deaths

With the heroin epidemic in the United States reaching deadlier heights, Jacksonville-based Lakeview Health drug and alcohol treatment center's Dr. Philip Hemphill is helping to explain why fentanyl is causing a new wave of overdoses. Because Fentanyl is approximately 40 to 50 times more potent than pharmaceutical grade heroin and often illegally purchased unknowingly by recreational users as heroin, the risk of death skyrockets.

29 Aug 2015

Telesta Therapeutics receives FDA BLA Filing Notification for MCNA

Telesta Therapeutics Inc. announced today that it has received its BLA Filing Notification for MCNA from the U.S. Food and Drug Administration. This formal letter communicates that the FDA has completed its initial review of Telesta's Biologics License Application (BLA) submitted on June 29, 2015 and has accepted it for filing.

29 Aug 2015

AMCP issues statement in response to FDA’s draft guidance requiring nonproprietary names for biological products

The Academy of Managed Care Pharmacy (AMCP) is disappointed in the Food and Drug Administration's (FDA's) draft guidance and proposed rule that calls for biologics, including reference products and biosimilars, to bear a nonproprietary name with an FDA-designated suffix.

28 Aug 2015

Researchers identify drugs that may enhance ability of TKI dasatinib to kill human cancer cells

Researchers have discovered how a common mutation in a high-risk leukemia subtype drives the cancer's aggressiveness and have identified drugs that may work with existing precision medicines to improve survival. St. Jude Children's Research Hospital scientists led the study, which was published online today in the journal Cancer Cell.

28 Aug 2015

New study provides framework for establishing value-based pricing for new cancer drugs

At a time when cancer drug prices are rising rapidly, an innovative new study provides the framework for establishing value-based pricing for all new oncology drugs entering the marketplace. Using a highly sophisticated economic model, researchers from Winship Cancer Institute of Emory University and Georgia Institute of Technology used an example of a new lung cancer drug.

28 Aug 2015

Researchers find way to trigger 'virus alert' that may help boost drug's ability to prevent cancer cells

Working with human cancer cell lines and mice, researchers at the Johns Hopkins Kimmel Cancer Center and elsewhere have found a way to trigger a type of immune system "virus alert" that may one day boost cancer patients' response to immunotherapy drugs. An increasingly promising focus of cancer research, the drugs are designed to disarm cancer cells' ability to avoid detection and destruction by the immune system.

27 Aug 2015

Health providers still prescribing expensive malaria drugs in Nigeria to patients who do not have malaria

Health providers trained to perform malaria rapid diagnostic tests (RDT) are still prescribing valuable malaria medicines to patients who do not have malaria, according to new research published in PLOS ONE.

27 Aug 2015

Nitroglycerin can be repurposed to treat cancer, researchers find

For over a century, nitroglycerin has been used medically - particularly in the treatment of angina, or chest pain. It is a safe, cheap and effective treatment. Now, according to the latest study in ecancermedicalscience, researchers find that nitroglycerin is the latest in a series of medicines that could be repurposed to treat cancer.

27 Aug 2015

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP).

27 Aug 2015

Pharmaceutical News

Preoperative statins linked to reductions in cardiac complications, mortality after noncardiac surgery

Benznidazole has significant antiparasitic activity, but does not reduce progression of Chagas cardiomyopathy

AMRI, Saneca Pharmaceuticals collaborate to develop and market opium-derived APIs

LCZ696 reduces aortic systolic blood pressure, pulse pressure in hypertensive patients

Educational program does not influence patients’ adherence to apixaban anticoagulant

TECOS analysis shows sitagliptin safe and effective in patients with type-2 diabetes, cardiovascular disease

ATTEMPT-CVD trial results show that ARBs may have better impact on CVD biomarkers

MRA therapy does not improve outcome in heart attack patients without heart failure

Cyclosporine drug does not improve outcomes in STEMI patients receiving PCI

Single dose of cocaine can impair ability to recognise negative emotions

BPC praises FDA draft guidance on nonproprietary naming of biological products

Fentanyl sold as heroin causing new wave of overdose deaths

Telesta Therapeutics receives FDA BLA Filing Notification for MCNA

AMCP issues statement in response to FDA’s draft guidance requiring nonproprietary names for biological products

Researchers identify drugs that may enhance ability of TKI dasatinib to kill human cancer cells

New study provides framework for establishing value-based pricing for new cancer drugs

Researchers find way to trigger 'virus alert' that may help boost drug's ability to prevent cancer cells

Health providers still prescribing expensive malaria drugs in Nigeria to patients who do not have malaria

Nitroglycerin can be repurposed to treat cancer, researchers find

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News